Literature DB >> 26776335

Phenotypic determination of carbapenemase producing enterobacteriaceae isolates from clinical specimens at a tertiary hospital in Lagos, Nigeria.

O O Oduyebo, O M Falayi1, P Oshun, A O Ettu.   

Abstract

AIMS AND
OBJECTIVES: Carbapenemase production among clinical isolates of Enterobacteriaceae has been widely reported with prevalence rates ranging from between 2.8% and 53.6%. The aim of this study was to assess the prevalence of carbapenemase production among clinical isolates of Enterobacteriaceae from a Tertiary Hospital in Lagos, Nigeria, and to characterize the type of carbapenemase produced.
MATERIALS AND METHODS: Carbapenemase production was detected phenotypically using a commercially available combination disc test (Rosco Diagnostica carbapenemase detection Neo-Sensitab) containing inhibitors to the various carbapenemase classes. The Neo-Sensitabs were used for Enterobacteriaceae isolates that were resistant after the initial antibiotic susceptibility testing with meropenem (10 μg).
RESULTS: A total of 177 Enterobacteriaceae isolates were investigated and 27 (15.2%) were carbapenem-resistant. From the 27 carbapenem non-susceptible isolates, 22 (12.4%) were carbapenemase producers while 5 (2.8%) exhibited carbapenem resistance due to extended spectrum beta-lactamase production. Of the 22 isolates that were positive for carbapenemase production, 15 (8.5%) were metallo beta-lactamase (MBL) producers, 6 (3.4%) produced oxacillinase-48 while 1 (0.5%) produced both MBL and Klebsiella pneumoniae carbapenemase. Hence, the overall prevalence of carbapenemase-producing Enterobacteriaceae in this study was 12.4%.
CONCLUSION: Carbapenemase-producing Enterobacteriaceae was indeed prevalent in our institution. The combination disc test was a cost effective and suitable method for the initial detection of carbapenemase-producing Enterobacteriaceae within the clinical setting especially when molecular detection methods are not available.

Entities:  

Year:  2015        PMID: 26776335     DOI: 10.4103/1117-1936.173973

Source DB:  PubMed          Journal:  Niger Postgrad Med J


  6 in total

1.  Carbapenemase-Producing Enterobacteriaceae Isolates from Edo State, Nigeria.

Authors:  Christiana Jesumirhewe; Burkhard Springer; Sarah Lepuschitz; Franz Allerberger; Werner Ruppitsch
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  A systematic review: the current status of carbapenem resistance in East Africa.

Authors:  Kenneth Ssekatawa; Dennis K Byarugaba; Edward Wampande; Francis Ejobi
Journal:  BMC Res Notes       Date:  2018-08-31

3.  Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.

Authors:  Degefu Beyene; Adane Bitew; Surafel Fantew; Amete Mihret; Martin Evans
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

4.  The Emergence of Klebsiella pneumoniae with Reduced Susceptibility Against Third Generation Cephalosporins and Carbapenems in Lagos Hospitals, Nigeria.

Authors:  Kabiru O Akinyemi; Rebecca O Abegunrin; Bamidele A Iwalokun; Christopher O Fakorede; Oliwia Makarewicz; Heinrich Neubauer; Mathias W Pletz; Gamal Wareth
Journal:  Antibiotics (Basel)       Date:  2021-02-01

5.  Cross-sectional survey of knowledge and attitudes of healthcare workers and community members toward the Ebola virus disease and antimicrobial resistance pathogens outbreaks in Nigeria.

Authors:  Ibrahim Yusuf; Auwalu Halliru Arzai; Muhammad Yusha U; Lawal Garba; Musa Haruna; Muhammad Ibrahim Getso
Journal:  Pan Afr Med J       Date:  2021-10-22

6.  Multidrug-Resistant and Carbapenemase-Producing Enterobacteriaceae in Addis Ababa, Ethiopia.

Authors:  Saba Gebremichael Tekele; Dejenie Shiferaw Teklu; Melese Hailu Legese; Daniel Gebretsadik Weldehana; Melaku Ashagrie Belete; Kassu Desta Tullu; Samuel Kinde Birru
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.